Business Wire

CA-CEPTON-TECHNOLOGIES

11.1.2021 12:02:50 CET | Business Wire | Press release

Share
World-class Lidar Crowd Analytics Solution Partnership to Transform Smart Spaces With Anonymized Crowd Perception

A ground-breaking lidar-based real-time crowd analytics solution has recently helped Orlando International Airport (MCO) create one of the world’s safest terminals during the COVID-19 pandemic.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005374/en/

Deployed by The Indoor Lab, the leading provider for monitoring real-time foot traffic using lidar sensors, the solution - called Safe Place™ - uses Cepton’s award-winning Helius™ Smart Lidar System. Helius enables The Indoor Lab to provide intelligent, anonymized, 3D tracking of people, thereby dramatically improving the usability, safety and cleanliness of large spaces. Further, The Indoor Lab’s ground-breaking visual analytics platform, leveraging the Helius Smart Lidar System, powers the Synect Evenflow Crowd Radar media lights in terminal 2 of the Orlando International Airport.

The project at Orlando International Airport is one of several early projects initiated by The Indoor Lab and Cepton as part of a strategic partnership announced today. The Indoor Lab is Cepton’s early-stage development and analytics partner shaping the future of lidar analytics. This partnership lays the foundation for long-awaited innovations that will save customers time and money, enable more efficient design of public and private commercial spaces, and add a much-needed capability to improve public safety during the COVID-19 pandemic and recovery.

Patrick Blattner, co-founder and Chief Product Officer of The Indoor Lab said: “We have a 15-year history of crowd tracking across retail, events, airports, and stadiums. So, when COVID-19 started spreading exponentially and negatively affected many public and private spaces, we consulted with leaders involved in drafting proposals for the International Franchise Association, including the use of lidar technology to help put the country back on a path towards normalcy. With public concerns focused on cleanliness of public and commercial spaces, we extended our Safe Place platform beyond occupancy and social distancing, creating the first proprietary real-time sanitization detection solution in the market. A Safe Place enabled environment ensures locations have been cleaned, distancing measures are followed, and safer occupancy levels are maintained. Our partnership with Cepton helped us deliver against this promise. Our patent-pending Safe Place platform with real-time cleaning detection is the first of its kind in the world.”

According to The Indoor Lab, the full solution implemented in Orlando led to a drastic improvement in people’s adherence to social distancing through Thanksgiving and into the busy holiday travel season. The unprecedented effectiveness of The Indoor Lab’s innovative crowd analytics solution relies on the unique, high point density and detection range of Cepton’s MMT® -based Vista® -series lidars and Cepton’s award-winning Helius system that provides object dimensions, locations and velocities at high accuracy. The mirrorless, frictionless and rotation-free MMT architecture enables lidars that are reliable and easy to integrate for both indoor and outdoor applications. In addition, Helius allows easy aggregation of data from multiple Cepton lidar sensors to form a comprehensive and extendable network for seamless tracking. For instance, this allows the anonymized tracking of the same person across large overlapping areas, which, according to The Indoor Lab, is another game-changing factor that differentiates Helius from other lidar solutions.

In the Orlando International Airport deployment, the Indoor Lab used seven Vista lidar sensors from Cepton to seamlessly cover nearly 100% of the terminal area of roughly 50,000 square feet, something that would otherwise have required significantly more video cameras, each consuming far more data and storage bandwidth compared to the lidars. Unlike video cameras, lidars also perform accurately 24/7 regardless of lighting conditions.

Another key advantage of lidar, compared to cameras, is that it does not capture biometric data. While lidar sensors provide information to help detect, track and classify objects accurately, they do not show facial features and skin/hair color, maximizing protection of people’s privacy and reducing analytical bias. “The great thing about lidar-based crowd analytics is that it is compliant with privacy laws. At the same time, the system can also integrate with point, tilt, zoom (PTZ) cameras to detect potential public safety risks, such as a bag left behind in a public space or people unexpectedly moving at high rates of speed,” explained Blattner.

The partnership between Cepton and The Indoor Lab extends beyond projects in airports. Using Cepton’s technology, The Indoor Lab is successfully monitoring real-time traffic globally across hotels, stadiums, large commercial venues and retail spaces, such as malls and stores. The Indoor Lab’s software provides state-of-the-art, real-time information on crowd density, as well as dwell times, motion tracking and speed of individuals. Using all of that data, enterprises can optimize their customers’ experience in their spaces – to manage queues, reduce crowding, optimize layout of aisles, walkways and shops, as well as address safety and security risks.

“After evaluating most of the lidar hardware and 3D perception software offerings on the market, The Indoor Lab has identified Cepton to be the leader with a combined solution that provides the point-cloud density, accuracy, reliability, and ease and cost of integration required to properly enable crowd analytics. Together with the Cepton team, we have successfully monitored and analyzed dense crowds in some of the most challenging environments,” said Patrick Mooney, co-founder and CTO at The Indoor Lab.

Dr. Jun Pei, Cepton’s co-founder and CEO, said: “We are grateful for the partnership with The Indoor Lab and for their adoption of Cepton’s cutting-edge technology to deploy their pathbreaking innovations into a range of diverse applications. The power of this partnership is already evident in the remarkable results recently showcased by The Indoor Lab with their other partners.”

“We worked closely with The Indoor Lab to ensure we were able to deliver the capabilities and accuracy needed for their smart space applications at an affordable price. Our Helius team built a ground-breaking solution that combines intelligent, powerful lidar perception with ease of integration and data efficiency. In a future where smart spaces are pivotal to positively transforming people’s experience in travel, retail, hospitality, entertainment and beyond, I’m confident that Helius will continue to set the benchmark for world-class anonymized perception needed by world-leading partners such as The Indoor Lab.”

Cepton will be showcasing its state-of-the-art lidar solutions at CES 2021 from January 11 to January 14, 2021. Please visit Cepton’s virtual booth (requires CES registration) for more information about Helius and Cepton’s full suite of lidar offerings for various markets. During CES, Cepton’s CMO Dr. T. R. Ramachandran will present at an online webinar “Lidar, What’s the Future ” on Tuesday Jan 12 at 2 p.m. (PST), hosted by North American Lighting (NAL). Additionally, Dr. Ramachandran will discuss how lidar is transforming smart cities in a virtual panel discussion “Smart City Roundtable: What is a Smart City ?” on Jan 13 at 2 p.m. (PST), also hosted by NAL. Join the sessions online to learn more about the transformational nature of lidar technology and how Cepton’s smart lidar solutions are uniquely suited for large scale deployments in smart city and smart spaces applications.

About Cepton Technologies, Inc.

Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT® -based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.

Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .

About The Indoor Lab

The Indoor Lab, is the leading provider for monitoring real-time foot traffic using lidar sensors. The Safe PlaceTM platform is the newest product within their portfolio of foot traffic analytic solutions and is shaping the safe return and re-opening for all businesses in the future. Beyond COVID-19, The Indoor Lab offers the most extensive combined experience in designing, developing, and deploying real-time location services for some of the most heavily trafficked retailers, monuments, airports, and stadiums worldwide. The founders were the first to introduce 3D lidar for public space tracking and have since become the market leaders delivering the most accurate privacy compliant tracking solutions in the world. For more information, visit www.theindoorlab.com and follow us on LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye